SpringWorks Therapeutics(SWTX) - 2024 Q4 - Annual Results

Financial Performance - SpringWorks Therapeutics, Inc. achieved preliminary U.S. net product revenue of $61.5 million for Q4 2024 and $172.0 million for the fiscal year ended December 31, 2024[4] - The company's total preliminary cash, cash equivalents, and marketable securities amounted to $461.9 million as of December 31, 2024[4] Audit Status - The financial information provided is unaudited and preliminary, with ongoing audits that may result in changes[5]